

CURRICULUM VITAE

NAME Stephen E.F. Spurgeon, MD

DATE May 9, 2024

Academic Rank: **Professor**, Internal Medicine/Hematology & Medical Oncology
Department/Division: Knight Cancer Institute, Oregon Health & Science University
Professional Address: Center for Health & Healing Building 2, 3303 SW Bond Ave., mail code OC13CT
Portland, OR 97239
Phone: 503-494-8950
Fax: 503-494-1552
spurgeos@ohsu.edu

EDUCATION

Undergraduate and Graduate:

1992-1996 Bachelor of Arts in biology, *Magna cum Laude*, Bowdoin College, Brunswick, ME
1998-2002 Doctorate in Medicine, *Magna cum Laude*, Jefferson Medical College, Philadelphia, PA

Postgraduate

2002-2025 Internship/Residency OHSU Internal Medicine
2005-2006 Chief Resident OHSU Internal Medicine
2006-2007 Fellowship OHSU Hematology & Medical Oncology

Licenses:

2005 Oregon Medical License #MD26034, active, next renewal 12/31/2021
2005 United States Medical Licensing Exam
2005 Drug Enforcement Administration, #BS9549873

Certification:

2005-2015 Diplomate in Internal Medicine, American Board of Internal Medicine, #263557
2009-2019 Diplomate in Medical Oncology, American Board of Internal Medicine, #263557
2009-present Diplomate in Hematology: American Board of Internal Medicine, #263557

Other:

National Provider Number #1194730606
National Cancer Institute Investigator Number #45477

PROFESSIONAL EXPERIENCE

Academic:

2005-2006 Chief Resident/Instructor in Medicine, Oregon Health & Science University
2008-2009 Chief Fellow, Hematology/Oncology, Oregon Health & Science University
2009-2015 Assistant Professor of Medicine, Oregon Health & Science University
2015-2022 Associate Professor of Medicine, Oregon Health & Science University
2019-present Distinguished Scholar in Leukemia and Lymphoma Research, Knight Cancer Institute, OHSU

Pharmacyclics LLC
Exhibit 2015
BeiGene v. Pharmacyclics
PGR2024-00009
EX2015.0001

2022-present Professor of Medicine, Oregon Health & Science University

Administrative:

2008-2009 Medical Director, Hematology/Oncology Moonlighting Program, OHSU
2009-2013. Disease Site Leader, Chronic Lymphocytic Leukemia Research, OHSU Knight Cancer Institute
2012-2013 Medical Director, Inpatient Hematologic Malignancies Service, OHSU
2011-present co-Chair, Clinical Research Review Committee, OHSU Knight Cancer Institute
2013-present Section Chief, Hematologic Malignancies, OHSU Knight Cancer Institute
2018-present Program Leader, Lymphoma and Chronic Leukemia Research, OHSU Knight Cancer Institute

Clinical:

2023-present Staff Physician, Celilo Cancer Center, The Dalles, OR
2017-2020 Attending Physician, Community Hematology & Medical Oncology, OHSU Knight Cancer Institute East Portland Office
2009-present Attending Physician, Hematologic Malignancies, Lymphoma/Myeloma and Autologous Transplant Inpatient Service, OHSU
2009-present Attending Physician, Lymphoid Malignancies Program, Division of Hematology & Medical Oncology

SCHOLARSHIP

Departmental

2004 Resident Teaching Award, Oregon Health & Science University
2005 Resident Teaching Award, Oregon Health & Science University
2005 Chief Resident, Instructor of Medicine, Oregon Health & Science University
2008 Chief Fellow, Oregon Health & Science University

Institutional

2003 Rose Award for Service Excellence, Oregon Health & Science University
2004 Laurell Erickson Gold Star Award, Oregon Health & Science University
2007 Rose Award for Service Excellence, Oregon Health & Science University
2008 Tartar Trust Fellowship Recipient, Oregon Health & Science University
2011 Golden Rose Award Nominee, Oregon Health & Science University
2013 Clinical Scholar Award, Knight Cancer Institute, Oregon Health & Science University
2014 Clinical Scholar Award, Knight Cancer Institute, Oregon Health & Science University
2018 Tech Transfer Award Winner, Oregon Health & Science University
2018-present Clinical Star Award, Oregon Health & Science University
2019-present Distinguished Scholar in Leukemia and Lymphoma Research, Knight Cancer Institute, Oregon Health & Science University
2021 Fellowship Appreciation Award, Division of Hematology & Medical Oncology, Oregon Health & Science University

Regional/National

2000 Hobart Armory Hare Honor Society, Jefferson Medical College

2000	Association of Pathology Honors Society, Jefferson Medical College
2001	<i>Alpha Omega Alpha</i> Medical Honor Society, Jefferson Medical College
2002	<i>Magna cum Laude</i> , Jefferson Medical College
2002	Annie Simpson General Medicine Prize, Jefferson Medical College
2002	Commencement Class Day Speaker (peer-elected), Jefferson Medical College
2014	Mantle Cell lymphoma Sub-Committee Appointee, National Cancer Institute, Bethesda, MD

Area(s) of Research/Scholarly Interest:

Pre-clinical Evaluation of Novel Therapeutics in Hematologic Malignancies
 Clinical Trials in Hematologic Malignancies with a special focus on lymphoma
 Outcomes in Hematologic Malignancies

Grants and Contracts: Federal (Include Title, Source, PI, Amount, Period and % Effort)

Active

None

Completed

“Novel Tyrosine Kinase Targets in Leukemia and Myeloproliferative Neoplasms”

Leukemia Lymphoma Society

Site PI: Druker (Spurgeon co-leader of clinical trials core). \$1,042,000., 2010-2016, 3%

Phase II Proof of Concept Trial to Study Kinase Inhibition in Relapsed/Refractory Leukemias

DHHS NIH NCI, 1R21CA159265-02

Site PI: Loriaux (Spurgeon clinical PI). \$206,566., 2011-2016, 5%

State and Local: (Include Title, Source, PI, Amount, Period and % Effort)

Active

Distinguished Scholar in Leukemia and Lymphoma Research

Endowment, OHSU Knight Cancer Institute

Unrestricted Project Funds \$470,218.; Endowment \$3,214,787.

Completed

Phase I/II Study of Vorinostat (SAHA), Cladribine, and Rituximab in newly diagnosed Mantle Cell Lymphoma

Tartar Trust

PI: Spurgeon. \$2,000., 2008-2009, 7%

Predicting Response to Dasatinib Treatment in Chronic Lymphocytic Leukemia

Medical Research Foundation of Oregon

PI: Spurgeon. \$40,000., 2012-2014, 10%

Knight Cancer Institute Clinical Scholar Award
Knight Cancer Institute at Oregon Health & Science University, Portland, OR
PI: Spurgeon, \$28,800., 2012-2014, 10% (salary/research support)

The human immune response during and following acute viral infections with and vaccinations against novel and emerging viruses
Distinguished Scholar Award, Knight Cancer Institute
Site PI: Messer, Spurgeon (evaluation of CLL population), \$50,000., 2021- 2023, no effort

Other Support: (Include Title, Source, PI, Amount, Period and % Effort)

Translational

Active

None

Completed

Evaluating BST-2 expression in lymphoid malignancies and the effects of BST-2 inhibition in lymphoid malignancies
SBI Biotech Co., Ltd.
PI: Spurgeon. \$50,000., 2011-2012, 4%

Gene expression profiling in CLL samples treated with CAL-101
Gilead Pharmaceuticals
PI: Spurgeon. \$45,500.00, 2011-2012, 4%

Mechanisms of Resistance to delta-isoform Specific Inhibition in Lymphoma and CLL
Gilead Pharmaceuticals
PI: Spurgeon. \$96,360.00, 2012-2013, 7%

BEAT AML
Leukemia and Lymphoma Society
Site PI: Druker (Spurgeon co-leader of clinical trials core). \$2,500,000., 2013-2018, 10%

Dual BTK and PI3K-delta Inhibition as a Potential Therapeutic Strategy in Mature Lymphoid Leukemias
Acerta Pharmaceuticals
PI: Spurgeon. \$92,400., 2014-2016, 8%

Evaluating ROR-1 expression and activity of the anti-ROR-1 antibody Cirmtuzumab in lymphoma
Oncternal Therapeutics
PI: Spurgeon, 2017-2019, \$35,000., 2%

MALT-1 inhibition in lymphoid malignancies
Schrodinger
PI: Spurgeon. \$88,941., 2021-2023, no effort

Clinical

Active

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects with Newly Diagnosed Mantle Cell Lymphoma
Janssen Pharmaceuticals
Site PI: Spurgeon, \$328,286., 2013-present, 2%

A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas.
Bristol Meyers Squibb.
Site PI: Spurgeon (national protocol planning committee), \$579,095., 2014-present 3%

A Phase 1/2 Proof-of-concept study of the combination of ACP-196 and ACP-319 in subjects with B-cell malignancies.
Acerta Pharma
Site PI: Spurgeon, \$581,264., 2015-present, 1%

A Phase 1B Dose Escalation and Dose Expansion Study of ONO/GS-4059 in Combination with Other Targeted Anti-Cancer Therapies in Subjects with B-cell Malignancies.
Gilead Sciences Inc.
Site PI: Spurgeon, \$954,607., 2016-present, 2%

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma, \$267,831.
Acerta Pharma
Site PI: Spurgeon, 2017-present, no effort

An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.
Beigene
Site PI: Spurgeon, \$164,954., 2018-present, 1%

EA9161 - A Randomized Phase III Study of the addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL).
NCTN
Site PI: Spurgeon, 2019-present, no effort

A Phase 3, Randomized Study of Zanubrutinib (BGB 3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.
Beigene

Site PI: Spurgeon, \$126,340., 2019-present, 1%

A041702 – A randomized Phase III study of Ibrutinib plus Obinutuzumab versus Ibrutinib plus Venetoclax and Obinutuzumab in untreated older patients (≥ 70 years of age) with chronic lymphocytic leukemia (CLL).

NCTN

2019-present, no effort

A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS-101 in Subjects with Hematological Malignancies.

Velos Bio Inc.

Site PI: Spurgeon, \$221,489., 2019-present, 3%

EA4181 - A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients ≤ 70 Years Old with Untreated Mantle Cell Lymphoma,

NCTN

Site PI: Spurgeon (*national planning committee, SWOG champion*), 2020-present, no effort

A Phase 1B, Multi-center, Open-label Study to determine the Safety, Pharmacokinetics, and Preliminary Efficacy of CC-99282 in combination with Obinutuzumab in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Celgene

Site PI: Spurgeon, \$668,050., 2020-present, 2%

A Phase Ib study evaluating the safety and efficacy of tafasitamab, aclaabrutinib, and obinutuzumab (TAO) in newly diagnosed chronic lymphocytic leukemia (CLL). Incyte

PI: Spurgeon (investigator initiated), 2023-present, \$607, 735.77, 4%

A Phase 1b trial evaluating the clinical activity of glofitamab plus Ibrutinib (GLIB) in previously untreated Mantle Cell Lymphoma.

Genentech, PI: Spurgeon (investigator initiated, multicenter), 2021-present, \$1,300,100.00
3%

A Phase 1b/2 study evaluating the safety and efficacy of Mosunetuzumab in combination with DA EPOCH in previously untreated c-Myc rearrangement positive high grade B Cell Lymphomas.

Genentech, PI: Spurgeon (investigator initiated, multicenter), 2023-present, \$1,008,018.62, 3%

A Phase 1, Open-Label, Multicenter, Dose Escalation Study Of SGR-1505 As Monotherapy In Subjects With Mature B-Cell Malignancies

Schrodinger

Site PI: Spurgeon, 2024-present, \$51, 628.00/patient, no effort

Completed

Phase I/II Study of Vorinostat (SAHA), Cladribine, and Rituximab in newly diagnosed Mantle Cell Lymphoma (MCL)

Merck & Co. Inc.

PI: Spurgeon (national PI - multicenter *investigator-initiated* study), \$278,973., 2008-2013, 7%

Phase II Study of Forodesine in Subjects with Chronic Lymphocytic Leukemia (CLL)

BioCryst Pharmaceuticals

Site PI: Spurgeon. 2008-2012, \$98,941., 2%

Phase I Sequential Dose Escalation study to investigate the Safety, Pharmacokinetics, Pharmacodynamics, and clinical activity of CAL-101 in patients with select, relapsed, or refractory hematologic malignancies

Gilead Pharmaceuticals

Site PI: Spurgeon. \$182,802.43, 2009-2012, 2%

A Phase I/II Study of TRU-016 in Patients with Previously Treated Chronic Lymphocytic Leukemia

Emergent Biosolutions

Site PI: Spurgeon. \$148,714., 2010-2011, 2%

A Phase II Study of Dasatinib in Chronic Lymphocytic Leukemia in Patients Who Exhibit in Vitro Dasatinib Sensitivity

Bristol Meyers Squibb

PI: Spurgeon (single-center, *investigator initiated*), \$200,000., 2010-2014, 10%

Safety of GNKG168 in Subjects with Relapsed or Refractory CLL”

Theradex

PI: Spurgeon (multicenter, national PI), \$211,019., 2011-2014, 8%

A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination with Idelalisib in Subjects with Relapsed or Refractory Hematologic Malignancies

Gilead Sciences Inc.

Site PI: Spurgeon, \$175,000., 2013-2016, 3%

A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia.

Gilead Sciences Inc.

Site PI: Spurgeon, \$164,846., 2013-2017, 2%

A phase 1b feasibility study of personalized kinase inhibitor therapy combined with induction chemotherapy for patients with newly diagnosed acute myelogenous leukemia (AML)

SWOG HOPE Award

Site PI: Loriaux and Spurgeon. \$199,947., 2015-2020

EA1411 - Intergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine

Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR).

NCTN

Site PI: Spurgeon, 2015-present, no effort

A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 (Umbralisib) Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL).

TG Therapeutics

Site PI: Spurgeon, \$287,823., 2016-2023, no effort

A Phase II study of intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Verastem Oncology

Site PI: Spurgeon (*investigator-initiated, PI Danilov*), \$144,250, 2019-2023, no effort

Multicenter Evaluation of SARS-CoV-2 Vaccines in Patients with CLL/SLL

Fred Hutchinson Cancer Center

Site PI: Spurgeon, \$36,000., 2021-2024, no effort

Targeting STAT-3 in Lymphoma (TASL)

Ionis

PI: Spurgeon (investigator initiated), 2021-2023, \$100,000., no effort

Hypertension in Patients Treated with Bruton Tyrosine Kinase Inhibitors for Lymphoid Malignancies: Treatment Efficacy and Cardiovascular Outcomes

Astra Zeneca

Site PI: Spurgeon, \$20,750., 2020-2021, no effort

Selected/Relevant Publications/Creative Work (underlined = first or last author). Google

Scholar H index = 28

Original Reports

1. **Spurgeon SE**, Hsieh YC, Rivadinera A, et al. Classification and regression tree analysis for the prediction of aggressive prostate cancer on biopsy. J Urol. 2006 Mar;175(3 Pt 1):918-22. PMID: 16469580.
2. **Spurgeon SE**, Mongoue-Tchokote S, Collins L, Priest R, Hsieh YC, Peters LM, Beer TM, Mori M, Garzotto M. Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy. Urology. 2007 May;69(5):931-5. PMID: 17482937.
3. Coates S, Barker A, **Spurgeon SE**. Reversible pulmonary toxicity due to lenalidomide. J Oncol Pharm Pract. 2012 Jun;18(2):284-6. Epub 2011 Jul 8. PMID: 21742815.
4. **Spurgeon SE**, Pindyck T, Okada C, et al. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. Leuk Lymphoma. 2011 Aug;52(8):1488-94. Epub 2011 May 31. PMID: 21623691.

5. Chandran R, Gardiner SK, Simon M, **Spurgeon SE**. Survival trends in mantle cell lymphoma in the United States over 16 years 1992-2007. *Leuk Lymphoma*. 2012 Aug;53(8):1488-93. Epub 2012 Feb 13. PMID: 22242824.
6. Tyner JW, Yang WF, Bankhead A 3rd, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, **Spurgeon SE**, et al. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. *Cancer Res*. 2013 Jan 1;73(1):285-96. Epub 2012 Oct 18. PMID: 23087056.
7. **Spurgeon SE**, Coffey G, Fletcher LB, et al. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. *J Pharmacol Exp Ther*. 2013 Feb;344(2):378-87. Epub 2012 Dec 7. PMID: 23220742.
8. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielewska E, Radford J, Stilgenbauer S, Dreyling M, Jędrzejczak WW, Johnson P, **Spurgeon SE**, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. *N Engl J Med*. 2013 Aug 8;369(6):507-16. Epub 2013 Jun 19. PMID: 23782157.
9. Chandran R, Gardiner SK, Smith SD, **Spurgeon SE**. Improved survival in hairy cell leukaemia over three decades: a SEER database analysis of prognostic factors. *Br J Haematol*. 2013 Nov;163(3):407-9. Epub 2013 Jul 24. PMID: 23889044.
10. Prins RC, Burke RT, Tyner JW, Druker BJ, Loriaux MM, **Spurgeon SE**. CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. *Leukemia*. 2013 Oct;27(10):2094-6. Epub 2013 Jul 31. PMID: 23900138.
11. Chandran R, Simon M, **Spurgeon SE**. Concurrent presentation of hodgkin lymphoma and multiple myeloma. *Case Rep Hematol*. 2013; 2013:398769. Epub 2013 Aug 20. PMID: 24027647.
12. Smith SD, Chen A, **Spurgeon SE**, Okada C, Fan G, Dunlap J, Brazier R, Maziarz R. Diffuse large B-cell lymphoma in adults aged 75 years and older: a single institution analysis of cause-specific survival and prognostic factors. *Ther Adv Hematol*. 2013 Dec;4(6):349-53. PMID: 24319570.
13. Byrd JC, Pagel JM, Awan FT, Forero A, Flinn IW, Deauna-Limayo DP, **Spurgeon SE**, Andritsos LA, Gopal AK, Leonard JP, Eisenfeld AJ, Bannink JE, Stromatt SC, Furman RR. A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. *Blood*. 2014 Feb 27;123(9):1302-8. Epub 2013 Dec 31. PMID: 24381226.
14. Burke RT, Meadows S, Loriaux MM, Currie KS, Mitchell SA, Maciejewski P, Clarke AS, Dipaolo JA, Druker BJ, Lannutti BJ, **Spurgeon SE**. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor. *Oncotarget*. 2014 Feb 28;5(4):908-15. 1484. PMID: 24659719.
15. Byrd JC, Pagel JM, Awan FT, Forero A, Flinn IW, Deauna-Limayo DP, **Spurgeon SE**, et al. A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. *Blood*. 2014 Feb 27;123(9):1302-8. Epub 2013 Dec 31. PMID: 24381226.
16. Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, **Spurgeon SE**, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman S, Li D, Jahn TM, Lannutti BJ, Ulrich RG, Yu AS, Miller LL, Furman RR. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 δ , for relapsed/refractory chronic lymphocytic leukemia. *Blood*. 2014 May 29;123(22):3390-7. Epub 2014 Mar 10. PMID: 24615777.
17. Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Coutre SE, Benson DM, Peterman S, Cho Y, Webb HK, Johnson DM, Yu AS, Ulrich RG,

- Godfrey WR, Miller LL, **Spurgeon SE**. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- δ , as therapy for previously treated indolent non-Hodgkin lymphoma. *Blood*. 2014 May 29;123(22):3406-13. Epub 2014 Mar 10. PMID: 24615776.
18. Kahl BS, **Spurgeon SE**, Furman RR, et al. A phase 1 study of the PI3K δ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). *Blood*. 2014 May 29;123(22):3398-405. PMID: 24615778.
 19. Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Coutre SE, Benson DM, Peterman S, Cho Y, Webb HK, Johnson DM, Yu AS, Ulrich RG, Godfrey WR, Miller LL, **Spurgeon SE**. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- δ , as therapy for previously treated indolent non-Hodgkin lymphoma. *Blood*. 2014 May 29;123(22):3406-13. Epub 2014 Mar 10. PMID: 24615776.
 20. Pagel JM, **Spurgeon SE**, Byrd JC, et al. Br J Haematol. Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR() therapeutic protein, for relapsed or refractory NHL patients. 2015 Jan;168(1):38-45. Epub 2014 Aug 22.Br J Haematol. 2015. PMID: 25146490.
 21. Geller MD, Pei Y, **Spurgeon SE**, Durum C, Leeberg NJ. Chronic lymphocytic leukemia with a FGFR3 translocation: case report and literature review of an uncommon cytogenetic event. *Cancer Genet*. 2014 Jul-Aug;207(7-8):340-3. Epub 2014 Sep 19. PMID: 25441688.
 22. Braun TP, Maxson JE, Agarwal A, Dunlap J, **Spurgeon SE**, Traer E. Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome. *Leuk Res Rep*. 2014 Dec 25;4(1):8-11. PMID: 25628989.
 23. Siegel MB, Liu SQ, Davare MA, **Spurgeon SE**, et al. Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma. *Oncotarget*. 2015 Aug 7;6(22):18921-32. doi: 10.18632/oncotarget.4214. PMID: 26254279.
 24. Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, **Spurgeon SE**, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. *Blood*. 2015 Aug 6;126(6):739-45. doi: 10.1182/blood-2015-03-635326. Epub 2015 Jun 9. PMID: 26059948.
 25. Paiva C, Godbersen JC, Soderquist RS, Rowland T, Kilmarx S, **Spurgeon SE**, et al. Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells. *PLoS One*. 2015 Nov 25;10(11):e0143685. PMID: 26606677.
 26. Gordon MJ, Raess PW, Young K, **Spurgeon SE**, Danilov AV. Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia. *Br J Haematol*. 2017 Nov;179(3):501-503. Epub 2016 Jul 8. PMID: 27391978.
 27. Leonard JT, Rowley JS, Eide CA, Traer E, Hayes-Lattin B, Loriaux M, **Spurgeon SE**, Druker BJ, Tyner JW, Chang BH. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. *Sci Transl Med*. 2016 Aug 31;8(354):354ra114. PMID: 27582059.
 28. Raess PW, Cascio MJ, Fan G, Press R, Druker BJ, Brewer D, **Spurgeon SE**. Concurrent STAT3, DNMT3A, and TET2 mutations in T-LGL leukemia with molecularly distinct clonal hematopoiesis of indeterminate potential. *Am J Hematol*. 2017 Jan;92(1):E6-E8. Epub 2016 Nov 18. PMID: 27761930.
 29. Gordon MJ, Tardi P, Loriaux MM, **Spurgeon SE**, et al. CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. *Leuk Res*. 2017 Feb;53:39-49. Epub 2016 Dec 12. PMID: 28013106.
 30. Borate U, Norris BA, Lo P, Tognon C, Tyner J, **Spurgeon SE**. Identification of targeted therapies for rare adult mature T-cell leukemia using functional ex vivo screening of primary patient samples. *Am J Hematol*. 2017 May;92(5):E64-E66. Epub 2017 Mar 10. PMID: 28181280.

31. Scott EC, Maziarz RT, **Spurgeon SE**, Medvedova E, Gajewski J, Reasor-Heard S, Park B, Kratz A, Thomas GV, Loriaux M, Cascio M, Podolak J, Gordon M, Botelho J, Stadtmauer E, Amaravadi R, Vogl DT. Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma. *Haematologica*. 2017 Jul;102(7):e261-e265. Epub 2017 Apr 6. PMID: 28385778.
32. Paiva C, Rowland TA, Sreekantham B, Godbersen C, Best SR, Kaur P, Loriaux MM, **Spurgeon SE**, Danilova OV, Danilov AV. SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia. *Haematologica*. 2017 Nov;102(11):1890-1900. doi: 10.3324/haematol.2017.170571. Epub 2017 Aug 24. PMID: 28838991.
33. Lachowiec C, Deodhar A, Kozin E, **Spurgeon SE**. Obinutuzumab is Effective in Chronic Lymphocytic Leukemia and Rheumatoid Arthritis After Rituximab Failure: A Case Report. *Am J Case Rep*. 2017 May 10;18:516-519. PMID: 28487504.
34. Edwards V DK, Sweeney DT, Ho H, Eide CA, Rofelty A, Agarwal A, Liu SQ, Danilov AV, Lee P, Chantry D, McWeeney SK, Druker BJ, Tyner JW, **Spurgeon SE**, Loriaux MM. Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. *Oncotarget*. 2018 May 15;9(37):24576-24589. PMID: 29872489.
35. Lachowiec C, White K, **Spurgeon SE**. Exaggerated arthropod assault: Eosinophilic dermatosis in a patient with small lymphocytic lymphoma. *Clin Case Rep*. 2018 Jul 17;6(9):1893-1895. doi: 10.1002/ccr3.1723. PMID: 30214788.
36. Gordon MJ, Churnetski M, Alqahtani H, Rivera X, Kittai A, Amrock SM, James S, Hoff S, Manda S, **Spurgeon SE**, Choi M, Cohen JB, Persky D, Danilov AV. Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. *Cancer*. 2018 Aug 1;124(15):3192-3200. Epub 2018 May 24. PMID: 29797667.
37. Gay ND, Kozin E, Okada C, Danilov AV, **Spurgeon SE**. Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia. *Leuk Lymphoma*. 2018 Sep;59(9):2258-2260. Epub 2017 Dec 18. PMID: 29249186.
38. Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK 5th, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, **Spurgeon SE**, et al. Functional Denomic Landscape of Acute Myeloid Leukaemia. *Nature*. 2018 Oct;562(7728):526-531. Epub 2018 Oct 17. *Nature*. 2018. PMID: 30333627.
39. Fay E, Herzig D, Sharzei K, **Spurgeon SE**. The First Report of Endoscopic Ultrasound-guided Intralesional Rituximab in a Patient With Mantle Cell Lymphoma Presenting With Isolated Colorectal Involvement. *Clin Lymphoma Myeloma Leuk*. 2020 Aug;20(8):e485-e487. Epub 2020 Mar 16. PMID: 32278675.
40. Khountham S, Shindiapina P, Mo X, Lachowiec C, Wiczer T, Mousa L, Rogers KA, Andritsos LA, Woyach JA, Byrd JC, **Spurgeon SE**, Awan FT. Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia. *Leuk Lymphoma*. 2021 Mar;62(3):716-721. Epub 2020 Nov 19. PMID: 33210562.
41. Raghunathan V, Fan G, Kittai AS, Okada C, Danilov AV, **Spurgeon SE**. A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia. *Eur J Haematol*. 2021 Feb;106(2):294-297. Epub 2020 Nov 2. PMID: 33089525.
42. Danilov AV, **Spurgeon SE**, Siddiqi T, et al. A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with

- relapsed/refractory chronic lymphocytic leukemia. Invest New Drugs. 2021 Mar 8. Epub ahead of print. PMID: 33683501.
43. Kittai AS, Best S, Thurlow B, Lam V, Hashiguchi T, Goodyear S, Persky DO, Okada C, Park B, **Spurgeon SE**, Danilov AV. Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies. Haematologica. 2021 Jan 28. Epub ahead of print. PMID: 33504141.
 44. Chopra P, **Spurgeon SE**. Worsening Kidney Function, Proteinuria, and Hematuria in a Patient with Chronic Lymphocytic Leukemia. Kidney 360. 2021 May 2 (5) 916-917. PMID: 35373070.
 45. Lam V, Best S, Kittai A, Orand K, **Spurgeon SE**, Tingting L, Danilov AV. Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukemia. Br J Clin Pharmacol. 2022 Feb;88 (2):836-841. PMID: 34196037.
 46. Wang M, Barrientos J, Furman RR, Mei M, Barr PM, Choi MY, de Vos S, Kallam A, Patel K, Kipps T, Rule S, Flanders K, Jessen KA, Ren H, Riebling PC, Graham P, King L, Thurston AW, Sun M, Schmidt EM, Lannutti BJ, Johnson DM, Miller LL, **Spurgeon SE**. Zilovetamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers. NEJM Evidence 2021 Oct 12. Online ahead of print.
 47. Orellana-Noia VM, Reed D, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins MP, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers AA, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, **Spurgeon SE**, et al. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood. 2022 Jan 20;139 (3):413-423. PMID: 34570876.
 48. Lyski ZL, Kim S, Lee DX, Sampson D, Raué HP, Raghunathan V, Ryan D, Brunton AE, Slifka MK, Messer WB, **Spurgeon SE**. Immunogenicity of Pfizer mRNA COVID-19 vaccination followed by J&J adenovirus vaccination in two patients with chronic lymphocytic leukemia. Case Rep Hematol. 2022 Feb 4; 2022:6831640. PMID: 35127183
 49. Lyski ZL, Kim MS, Xthona Lee D, Raué HP, Raghunathan V, Griffin J, Ryan D, Brunton AE, Curlin ME, Slifka MK, Messer WB, **Spurgeon SE**. Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia. Blood Adv. 2022 Feb 22;6 (4):1207-1211. PMID: 34872103.
 50. Barr PM, Smith SD, Roschewski MJ, O'Brien SM, Sharman JP, Melear JM, Patel P, Calvo R, Yang H, **Spurgeon SE**. Phase ½ study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma. Leuk Lymphoma. 2022 Feb 24;1-5. PMID: 35200084
 51. Kim MS, Banerjee T, Chen A, Danilov A, MacKinnon R, Thurlow B, Thakurta S, Orand K, Degnin C, Park B, **Spurgeon SE**. A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma. Leuk Lymphoma 2022 Mar 9;1-3. PMID: 35263204
 52. Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernández-Rivas JÁ, Hong X, Kim SJ, Lewis D, Mishima Y, Özcan M, Perini GF, Pocock C, Song Y, **Spurgeon SE**, et al. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle Cell Lymphoma. N Eng J Med. 2022 Jun 30;386 (26):2482-2494. Epub 2022 Jun 3. PMID: 35657079
 53. LeBlanc FR, Hasanali ZS, Stuart A ..., **Spurgeon SE**, et al. Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma. Oncotarget. 2022 Aug; 16;13:986-1002. PMID36093297.
 54. Bottomly D, Long N, Schults AR, Kurtz SE, Tognon CE, Johnson K, Abel M, Agarwal A, Avaylon S, Benton E, Blucher A, Borate U, Braun TP, Brown J, Bryant J, Burke R, Carlos A, Chang BH, Cho HJ, Christy S, Coblentz C, Cohen AM, d'Almeida A, Cook R, Danilov A, Dao

- KT, Degnin M, Dobb J, Eide CA, English I, Hagler S, Harrelson H, Henson R, Ho H, Joshi SK, Junio B, Kaempf A, Kosaka Y, Laderas T, Lawhead M, Lee H, Leonard JT, Lin C, Lind EF, Liu SQ, Lo P, Loriaux MM, Luty S, Maxson JE, Macey T, Martinez J, Minnier J, Montebianco A, Mori M, Morrow Q, Nelson D, Ramsdill J, Rofelty A, Rogers A, Romine KA, Ryabinin P, Saultz JN, Sampson DA, Savage SL, Schuff R, Searles R, Smith RL, **Spurgeon SE**, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. *Cancer Cell*. 2022 Aug 8;40(8):850-864.e9. doi: 10.1016/j.ccell.2022.07.002. Epub 2022 Jul 21. PMID: 35868306
55. Torka P, Kambhampati S, Chen L, Wang X, Chen C, Vuong D, Qin H, Muir A, Orand K, Borja I, Lynne Smith D, Herrera AF, **Spurgeon SEF**, et al. Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. *Blood Cancer J*. 2023 Jan 11;13(1):9. PMID: 36631449
 56. Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins M, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers A, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, **Spurgeon SE**, et al. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. *Blood*. 2022 Jan 20;139(3):413-423. PMID: 34570876.
 57. Banerjee T, Newman M, Chen A, Maziarz RT, Schachter L, **Spurgeon SE**, Vallurupalli A. A retrospective single-center analysis of CD-19 directed CAR T-cell therapy in relapsed/refractory mantle cell lymphoma. *Leuk Lymphoma*. 2023 Jun 7:1-4. Online ahead of print. PMID: 37287113
 58. David KA, Sundaram S, Kim SH, Vaca R, Lin Y, Singer S, Malecek MK, Carter J, Zayac A, Kim MS, Reddy N, Ney D, Habib A, Strouse C, Graber J, Bachanova V, Salman S, Vendiola JA, Hossain N, Tsang M, Major A, Bond DA, Agrawal P, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Berg S, Glantz M, Goldlust SA, Folstad M, Kumar P, Ollila TA, Cai J, **Spurgeon S**, et al. Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers. *Am J Hematol*. 2023 Jun;98(6):900-912. Epub 2023 Apr 5. PMID: 36965007
 59. Agrawal P, David KA, Chen Z, Sundaram S, Kim SH, Vaca R, Lin Y, Singer S, Malecek MK, Carter J, Zayac A, Kim MS, Reddy N, Ney D, Habib A, Strouse C, Graber J, Bachanova V, Salman S, Vendiola JA, Hossain N, Tsang M, Major A, Gandhi MK, Keane C, Bond DA, Folstad M, Chang J, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Berg S, Glantz M, Goldlust SA, Matnani R, Kumar P, Ollila TA, Cai J, **Spurgeon SE**, et al. EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. *Leuk Lymphoma*. 2023 May;64(5):1026-1034. Epub 2023 Mar 24. PMID: 36960939
 60. Ujjani CS, Gooley TA, **Spurgeon SE**, et al. Diminished Humoral and Cellular Responses to SARS-CoV-2 Vaccines in Patients with Chronic Lymphocytic Leukemia. *Blood Adv*. 2023 Sep 12;7(17):4728-4737. PMID: 36516082
 61. Samples L, Voustinas JM, Fakhri B, Khaiavian S, **Spurgeon SE**, et al. Hypertension Treatment in Patients Receiving Ibrutinib: A Multicenter Retrospective Study *Blood Adv* 2024 Feb 2;8(9):2085-2093. PMID: 38315043

Reviews

1. **Spurgeon SE**, Yu M, Phillips JD, Epner EM. Cladribine: not just another purine analogue? *Expert Opin Investig Drugs*. 2009 Aug;18(8):1169-81. doi: 10.1517/13543780903071038. PMID: 19604118.
2. Stephens DM, **Spurgeon SE**. Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion. *Ther Adv Hematol*. 2015 Oct;6(5):242-52. doi:

10.1177/2040620715592569. PMID: 26425337; PMCID: PMC4556969.

3. **Spurgeon SE**, Till BG, Martin P, Goy AH, Dreyling MP, Gopal AK, LeBlanc M, Leonard JP, Friedberg JW, Baizer L, Little RF, Kahl BS, Smith MR. Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. J Natl Cancer Inst. 2016 Dec 31;109(1):djw263. doi: 10.1093/jnci/djw263. PMID: 28040733; PMCID: PMC6059122.

Book Chapters

1. Shapiro SS, **Spurgeon SE**. Hematology: Coagulation Problems in SLE. Systemic Lupus Erythematosus, RJ Lahita, ed., 4th ed., Churchill Livingstone 2004.
2. Chandran R, Hakki M, and **Spurgeon SE**: Infections in Leukemia. Sepsis, In Tech Publishing, 2012.

Selected Abstracts & Posters

1. **Spurgeon, S**, Menajovsky L.B. The Incidence of Symptomatic Upper Extremity Deep Vein Thrombosis Associated with Peripherally Inserted Central Venous Catheters. Sixth Annual Anticoagulation conference, Washington DC, 2001.
2. **Spurgeon S**. Pneumococcal Sepsis. Associate Member poster presentation, Oregon American College of Physicians annual meeting, Eugene, OR, 2002.
3. **Spurgeon S**, Riavadeneira A, Peters LM, et al. Prediction of Aggressive Prostate Cancer on Biopsy Using Classification and Regression Tree Analysis (CART). Proc Am Soc Clin Onc 23:435, 2004.
4. Garzotto M, Collins L, Priest R, **Spurgeon S**, et al. Nomogram for the prediction of high-grade prostate cancer on ultrasound-guided needle biopsy. Proc Am Soc Clin Onc 23 (16S):408s, 2005.
5. **Spurgeon S**, Garzotto M, Collins L, et al. Utility of PSA doubling time (PSADT) in the detection of prostate cancer in men with a serum PSA < 10 ng/ml. Proc Am Soc Clin Onc 23 (16S):408s, 2005.
6. **Spurgeon S**, Pindyck T, Okada C, et al. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts), **116**: 4910, 2010.
7. Tyner J, **Spurgeon S**, Fletcher L, et al. A Small-Molecule Inhibitor Screen Rapidly Identifies Therapeutic Targets and Individualized Therapeutic Strategies in Patients with Acute and Chronic Leukemias. Blood (ASH Annual Meeting Abstracts), **116**: 2754, 2010.
8. Tyner J, Mayer L, Tardi P, Fletcher L, **Spurgeon S**, et al. Evaluation of CPX-351 (cytarabine: daunorubicin) Liposome Injection Anti-Leukemic Activity Against Primary Patient Leukemia Cells. Blood (ASH Annual Meeting Abstracts), **116**: 2886, 2010.
9. **Spurgeon S**, Fletcher L, Tyner J, et al. P505-15, a highly selective SYK inhibitor, shows significant activity in primary CLL cells and is synergistic with fludarabine at low concentrations. Blood (ASH Annual Meeting Abstracts), **116**: 2839, 2010.
10. Kahl B, Byrd J, Flinn I, Wagner-Johnston N, **Spurgeon S**, et al. **Clinical** Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110 δ , In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Blood (ASH Annual Meeting Abstracts), **116**: 1777, 2010.
11. Furman R, Byrd J, Brown J..., **Spurgeon S**, et al. CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110 δ , Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts), **116**: 55, 2010.
12. Sher T, Azar J, **Spurgeon S**, et al. Forodesine, a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Shows Clinical Activity In a Phase 2 Trial In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL) – Interim Analysis Blood (ASH Annual Meeting

- Abstracts), **116**: 1397, 2010.
13. **Spurgeon S**, Chen A, Okada C, et al. A phase I/II study of vorinostat (SAHA), cladribine (2-CdA), and rituximab shows significant activity in previously untreated mantle cell lymphoma. (ASCO Annual Meeting Abstracts), Abstract #84353, 2011.
 14. Prins R, **Spurgeon S**, Tyner J, et al. CX-4945, An Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Hematologic Malignancies, Blood (ASH Annual Meeting Abstracts) **118**: 3512, 2011.
 15. **Spurgeon S**, Chen A, Okada C, et al. A Phase I/II Study of Vorinostat (SAHA), Cladribine (2-CdA), and Rituximab Shows Significant Activity in Previously Untreated Mantle Cell Lymphoma Blood (ASH Annual Meeting Abstracts), **118**: 441, 2011.
 16. Pagel J, **Spurgeon S**, Awan F, et al. Phase 1 Study of TRU-016, An Anti-CD37 SMIP™ Protein in Relapsed and/or Refractory NHL Patients. Blood (ASH Annual Meeting Abstracts), **118**: 1636, 2011.
 17. Awan F, Pagel J, Andritsos L, Gopal A, Furman R, **Spurgeon S**, et al. **Phase 1 Study of Tru-016**, An Anti-CD37 SMIP™ Protein in Naïve and Relapsed and/or Refractory CLL Patients Blood (ASH Annual Meeting Abstracts), **118**: 1792, 2011.
 18. **Spurgeon S**, Fletcher L, Meadows S, Lannutti B, Burke R, Chen Y, Druker B, Loriaux M. Phosphoinositide 3'kinase (PI3K) Delta Inhibition with CAL-101 (GS1101) Significantly Alters Chemokines and Shows Increased *in Vitro* Activity in Unmutated IgVh CLL Compared to Mutated IgVh Samples. Clin. Lymph. Myel. & Leuk. Suppl. (XIV International Workshop on Chronic Lymphocytic Leukemia), 2.31, S178, 2011.
 19. Brown J, Jahn T, Furman R, Leonard J, **Spurgeon S**, et al. Patterns of Nodal Response and Lymphocytosis in Patients Receiving the Selective Phosphatidylinositol 3-Kinase Delta Inhibitor, CAL-101 (GS-1101) Alone or in Combination with Rituximab or Bendamustine. Clin. Lymph. Myel. & Leuk. Suppl. (XIV International Workshop on Chronic Lymphocytic Leukemia), 5.43, S272, 2011.
 20. Prins R, Fletcher L, Burke R, Loriaux M, Druker B, **Spurgeon S**. CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Exhibits CLL Antitumor Activity. Clin. Lymph. Myel. & Leuk. Suppl. (XIV International Workshop on Chronic Lymphocytic Leukemia), 2.31, S278, 2011.
 21. **Spurgeon SE**, Sharma K, Claxton DF, et al. Vorinostat (SAHA), Cladribine, and Rituximab in Previously Untreated Mantle Cell Lymphoma: Updated Results From a Phase I/II Trial. Blood (ASH Annual Meeting Abstracts), **120**: 3675, 2012.
 22. Burke RT, Clarke A, Meadows SA, ... **Spurgeon SE**. A Potential Therapeutic Strategy for Chronic Lymphocytic Leukemia by Combining GS-1101, a PI3 kinase Delta (PI3K δ) Inhibitor and a Novel Highly Selective Spleen Tyrosine Kinase (Syk) Inhibitor, GS-9973 Blood (ASH Annual Meeting Abstracts), **120**: 3876, 2012.
 23. Smith SD, Okada C, Chen AI, **Spurgeon SE**, et al.. Prognostic Features, Treatments, and Disease-Specific Mortality Among Patients with Diffuse Large B-Cell Lymphoma Over the Age of 75: A Single-Center Retrospective Analysis. Blood (ASH Annual Meeting Abstracts), **120**: 3673, 2012.
 24. Prins RC, Burke RT, Loriaux MM, Druker BJ, and **Spurgeon SE**. CX-4945, an Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Exhibits Synergy When Combined with the PI3K- Δ Inhibitor GS-1101 or Fludarabine. Blood (ASH Annual Meeting Abstracts), **120**: 1163, 2012.
 25. Chandran R, Gardiner S, Smith SD, and **Spurgeon SE**. Improved Survival in Hairy Cell Leukemia Over Three Decades: A SEER Database Analysis of Prognostic Factors. Blood (ASH Annual Meeting Abstracts), **120**: 2891, 2012.
 26. Sharma K, Leshchenko V, Hasanali Z, Stuart A, Shimko S, **Spurgeon SE**. Combined Epigenetic and immunotherapy for Newly Diagnosed Mantle Cell Lymphoma: Correlative Studies Suggest the Importance of Enhanced ADDCC, Mechanisms of Resistance and

Cyclin D1 Nuclear Localization Genotype. (ASH Annual Meeting Abstracts), Blood, 122:3063, 2013.

27. Kahl BS, **Spurgeon SE**, Furman FF. Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110 δ (PI3K δ), in patients with relapsed or refractory mantle cell lymphoma (MCL). J Clin Oncol 31, (suppl; abstr 8519), 2013.
28. Chandran R, Gardiner S, Fenske T, **Spurgeon SE**. Survival Trends in T cell prolymphocytic leukemia: A SEER database analysis. 11th International Ullmann Chicago Lymphoma Symposium, 2014.
29. Barr PM, **Spurgeon SE**, Abella E, et al. Phase 2 trial of GS-9973, a selective syk inhibitor, and idelalisib (idela) in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). (ASCO Annual Meeting Abstracts), Abstract # 129489 2014.
30. Wang M, Rule S, Martin P, et al. **Spurgeon S**, et al. Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study. Blood (ASH Annual Meeting, Abstract 2253), 2014; 124 (21).
31. Scott E, Vogl D, Reasor-Heard S, Floyd K, Medvedova E, **Spurgeon S**, et al. A Phase I Study of Hydroxychloroquine with Infusional Cyclophosphamide, Pulse Dexamethasone and Rapamycin in Patients with Relapsed or Refractory Multiple Myeloma. Blood (ASH Annual Meeting, Abstract 3449), 2014; 124 (21).
32. **Spurgeon S**, Sharma K, Claxton D, et al. Final Results of a Phase 1-2 Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) Relapsed B-Cell Non-Hodgkin's Lymphoma and Previously Untreated Mantle Cell Lymphoma. Blood (ASH Annual Meeting, Abstract 1714), Blood, 2014; 124 (21).
33. Chen A, Okada C, Gay N, Reiss P, **Spurgeon S**, et al. Consolidative Autologous Stem Cell Transplant for Double Hit Lymphoma. Blood (ASH Annual Meeting, Abstract 3993), 2014; 124 (21).
34. Siegel M, MD, Davare M, Liu S, **Spurgeon S**, et al. The Bromodomain Inhibitor CPI203 Demonstrates Preclinical Synergistic Activity with Bortezomib in Drug Resistant Myeloma. Blood (ASH Annual Meeting, Abstract 4702), 2014; 124 (21).
35. Chandran R, Gardiner SK, Fenske TS, **Spurgeon SE**. Survival trends in T cell prolymphocytic leukemia: A SEER database analysis. Leuk Lymphoma. 2016;57(4):942-4. doi: 10.3109/10428194.2015.1076932. Epub 2015 Sep 17. PMID: 26292711.
36. Kozin EL, **Spurgeon SE**. Upfront CLL treatment with single agent obinutuzumab. J Clin Oncol 33, 2015 (suppl; abstr e18039).
37. Davies AJ, Jurczak W, Byrd JC, **Spurgeon SE**, et al. Idelalisib monotherapy and durable responses in patients with relapsed or refractory Waldenstroms Macroglobulinemia (WM). J Clin Oncol 33, 2015 (suppl; abstr 8532).
38. Coutre S, Leonard J, Flowers C, Davies A, Jurczak W, Byrd J, **Spurgeon SE**, et al. Idelalisib Monotherapy Results in Durable Responses in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia. 20th Congress of the European Hematology Association, June 2015. Vienna, Austria.
39. Paiva C, Godbersen C, Danes CG, **Spurgeon SE**, et al. Pevonedistat Sensitizes Diffuse Large B-Cell Lymphoma Cells to Death Receptor Ligand-Mediated Apoptosis. Blood 2015 126:3994.
40. **Spurgeon SE**, Cook R, Traer E, et al. A Phase II Pilot Study of Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using an in Vitro Kinase Inhibitor Panel to Select Individualized, Targeted Therapies. Blood 2016 128:4051.
41. Paiva C, Rowland TA, Sreekantham B, Godbersen C, Best SR, Kaur P, Loriaux MM, **Spurgeon SE**, et al. SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia. Haematologica. 2017 Nov;102(11):1890-1900. Epub 2017 Aug 24. PMID: 28838991; PMCID: PMC5664393.

42. Sweeney T, **Spurgeon SE**, Tyner JW, et al. Colony Stimulating Factor 1 Receptor (CSF1R) As a Potential Novel Therapeutic Target in CLL. *Blood* 2018 126:4439. doi: 10.1182/blood-2018-05-851911.
43. Barr P, Smith SD, Roschewski M, ..., **Spurgeon SE**. Acalabrutinib combined with PI3K-delta inhibitor ACP-319 in patients with relapsed/refractory B-cell malignancies (ASCO annual meeting, 2018).
44. **Spurgeon SE**, Sharma K, Claxton DF, et al. Phase 1-2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma. *Br J Haematol*. 2019 Sep;186(6):845-854. doi: 10.1111/bjh.16008. Epub 2019 Jun 9. PMID: 31177537.
45. **Spurgeon SE**, Sharma K, Claxton DF, et al. Phase 1-2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma. *Br J Haematol*. 2019 Sep;186(6):845-854. Epub 2019 Jun 9. PMID: 31177537.
46. Kittai AS, Best S, Thurlow B, Lam V, Hashiguchi T, Goodyear S, Persky DO, Okada C, Park B, **Spurgeon SE**, Danilov AV. Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies. *Haematologica*. 2021. Epub ahead of print. PMID: 33504141.
47. Barrientos WM, Furman RR, Mei M, ..., **Spurgeon SE**. A ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma, 2020.
48. David KA, Sundaram S, Kim SE, ... **Spurgeon SE**, et al. Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era, *Journal: Blood* 2020.136 (Supplement 1): 24–26.
49. Orellana-Noia VM, Reed D, Sen J, ..., **Spurgeon SE**, et al. CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions. *Journal: Blood* 2020.136 (Supplement 1):27–28.
50. Agrawal P, David KA, Chen Z, ... **Spurgeon SE**, et al. EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort. *Journal: Blood* 2020.136 (Supplement 1): 4–6.
51. Wang M, Mei M, Barr PM, ... **Spurgeon SE**. Phase 1 Dose Escalation and Cohort Expansion Study of the Anti-ROR1 Antibody-Drug Conjugate Zilovertamab Vedotin (MK-2140) for the Treatment of Non-Hodgkin Lymphoma. *Blood* (2021) 138 (Supplement 1): 528.
52. Lyski ZL, Kim MS, Xthona Lee D, ..., **Spurgeon SE**. Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia. *Blood* (2021) 138 (Supplement 1): 528.
53. Danilov AV, Lam V, Thurlow B, **Spurgeon SE**, et al. Final Results of a Phase 1/2 Study of SYK Inhibitor Entospletinib in Combination with Obinutuzumab in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). *Blood* (2021) 138 (Supplement 1): 2643.
54. Orellana-Noia VM, Reed DR, McCook AA, **Spurgeon SE**, et al. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. *Blood* (2022) 139 (3): 413–423.
55. **Spurgeon SE**, Mei M, Barr PM, et al. Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma. *Blood* (2022) 140 (Supplement 1): 6640–6641.
56. Shouse GP, Chen L, Siddiqi T, Muir A, Brown JR, **Spurgeon SE**, Danilov A. A Phase II Study of Intermittent Duvelisib Dosing in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). *Blood* (2023) 142 (Supplement 1): 6531.

57. Kittai AS, Huang Y, Miller S, **Spurgeon SE**, et al. Outcomes of Patients with Richter Transformation without Prior Chemoimmunotherapy for CLL/SLL: An International Multicenter Retrospective Study. *Blood* (2023) 142 (Supplement 1): 497.
58. Ujjani CS, Gooley T, Siddiqi T..., **Spurgeon SE**, et al. Incidence and Management of COVID-19 Infections in Vaccinated Patients with CLL. *Blood* (2023) 142 (Supplement 1): 5149.

Invited Lectures, Conference Presentations or Professorships:

International and National

2009

Dasatinib for CLL, City of Hope Hematologic Malignancies Grand Rounds, Duarte, CA
Dasatinib for CLL, UC Davis Fellows Conference, Sacramento, CA

2010

CLL: The Present and the Future, UC Davis Medical Oncology Grand Rounds, Sacramento, CA
Transplant in CLL, Southwest Oncology Group (SWOG) Leukemia Committee Fall Meeting: San Francisco, CA

2011

A phase I/II study of vorinostat (SAHA), cladribine (2-CdA), and rituximab shows significant activity in previously untreated mantle cell lymphoma, American Society of Hematology* Atlanta, GA

Ofatumumab for Relapsed/Refractory CLL, Santa Barbara Oncology, Santa Barbara, CA
Ofatumumab for Relapsed/Refractory CLL, Utah Hematology/Oncology, Ogden, UT

2012

Treatment of Fludarabine Refractory CLL, Nevada Cancer Institute Oncology Grand Rounds: Las Vegas, NV
Treatment options for Relapsed Mantle Cell Lymphoma, Ventura Oncology, Ventura, CA

2013

Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110 δ (PI3K δ), in patients with relapsed or refractory mantle cell lymphoma (MCL), American Society of Clinical Oncology Annual Meeting,* Chicago, IL

Rationale for Dual Syk and PI3K inhibition in CLL, Gilead Sciences: GS-103 Investigator Meeting, San Francisco, CA

Idelalisib plus GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor, IWCLL Young Investigators Meeting,* Koln, Germany. *abstract chosen for oral presentation

2014

Novel targets in CLL: CD37, First Annual Summit on Chronic Lymphocytic Leukemia, Whistler, BC, Canada

CLL: The Basics, Genentech Inc., San Francisco, CA

2015

Ibrutinib in Mantle Cell Lymphoma: Glass Half-Full? Second Annual Summit on Chronic Lymphoid Malignancies, Whistler, BC, Canada

2016

Chronic Lymphocytic Leukemia. Highlights of the ASH Asia-Pacific, Brisbane, Australia

2018

Lymphoma. Best of ASCO, San Diego, CA

Revolutionizing the paradigm and Prognosis of B-cell Malignancies with BTK Inhibitors. Hospital Grand Rounds, Sutter Tracy Community Hospital, Stockton, CA

Revolutionizing the paradigm and Prognosis of B-cell Malignancies with BTK Inhibitors. Redlands Community Hospital Grand Rounds, Redlands, CA

2019

Update in B cell Malignancies. Pomona General Hospital, Pomona, CA

Betting on BTK Inhibitors in CLL: Where are we Now and Where are we Going. American Society of Health-System Pharmacists (ASHP) Satellite Symposia. Las Vegas, NV

2021

Navigating Evolving Paradigms in B-Cell Malignancies. Medicine Grand Rounds: Interfaith Medical Center, Brooklyn, NY

How I Treat CLL. Onc Live (<https://www.onclive.com>)

Integrated Approaches to Optimizing Care of Patients with Chronic Lymphocytic Leukemia
Virtual Advisory Board

2024

How I use MRD in CLL: Whistler Summit on Hematologic Malignancies, Whistler BC, CANADA

Glofitamab plus Ibrutinib in Mantle Cell Lymphoma: Whistler Summit on Hematologic Malignancies, Whistler BC, CANADA

Zilovertamab Vedotin Targeting of ROR1 in Mantle Cell Lymphoma, Whistler Summit on Hematologic Malignancies, Whistler BC, CANADA

Regional and Local

2009

CLL, Leukemia and Lymphoma Society Patient Education Series, Eugene, OR

Update in Lymphoma, OHSU American Society of Clinical Oncology Updates, Portland, OR

Follicular Lymphoma: Lymphocare: Why Should we Care? Hematology/Oncology Fellows Case Conference/Journal Club, Oregon Health & Science University, Portland, OR

2010

What Every Fellow Should Know About CLL, OHSU Hematology/Oncology Fellows Grand Rounds, Oregon Health & Science University, Portland, OR

Update in chronic lymphocytic leukemia, OHSU ASH Hematology Update: Portland, OR
Refractory CLL, City Wide Journal Club, Portland, OR

Lymphatic and Blood Based Cancers, OHSU Physician's Assistant Review Course: Portland, OR

CLL: Significant Progress but a Long Way to Go, Leukemia & Lymphoma Society. Oregon Blood Cancer Conference, Oregon Convention Center, Portland, OR

2011

What Every Fellow Should Know About CLL, OHSU Hematology/Oncology Fellows Grand Rounds, Oregon Health & Science University, Portland, OR

Waldenstrom's Macroglobulinemia, Leukemia and Lymphoma Society Patient Support Group Lake Oswego, OR

CLL, Leukemia and Lymphoma Society Patient Education Series, Lake Oswego, OR

Update in chronic lymphocytic leukemia, OHSU ASH Hematology Update: Portland, OR

Chronic Leukemias, Northwest Bone Marrow Transplant Program Biennial Transplant Conference, Portland, OR

Chronic Lymphocytic Leukemia, not so boring after all? OHSU Internal Medicine Grand Rounds *Ofatumumab for relapsed/refractory CLL*, St. Joseph's Regional Medical Center, Lewiston, ID

Initial Treatment of Mantle Cell Lymphoma: an OHSU perspective, OHSU Center for Hematologic Malignancies Grand Rounds, Portland, OR

An Update on Kinase Inhibitor Therapy in CLL, OHSU Center for Hematologic Malignancies Grand Rounds, Portland, OR

2012

What Every Fellow Should Know About CLL, OHSU Hematology/Oncology Fellows Grand Rounds, Oregon Health & Science University, Portland, OR

Bendamustine for CLL, Good Samaritan Hospital, Corvallis, OR

CLL, Leukemia and Lymphoma Society Patient Education Series, Lake Oswego, OR

Update in chronic lymphocytic leukemia, OHSU ASH Hematology Update, Portland, OR

Treatment update for relapsed/refractory CLL including novel Therapies, OHSU Center for Hematologic Malignancies Grand Rounds, Portland, OR

Mantle Cell Lymphoma from a Chemo and BMT perspective, OHSU Center for Hematologic Malignancies Grand Rounds, Portland, OR

Hairy Cell Leukemia, OHSU Center for Hematologic Malignancies Grand Rounds, Portland, OR

CK2 inhibition in Hematologic Malignancies, Joint Grey and Druker Lab Meeting, Knight Cancer Institute at OHSU, Portland, OR

Mantle Cell Lymphoma, Lymphoma Research Foundation, Ask the Doctor, Portland, OR
Ofatumumab for Relapsed/Refractory CLL, Salem Cancer Center, Salem, OR

Bendamustine for the treatment of relapsed CLL, Knight Cancer Institute Community Hematology and Oncology, Beaverton, OR

2013

What Every Fellow Should Know About CLL, OHSU Hematology/Oncology Fellows Grand Rounds: Portland, OR

CLL, Leukemia and Lymphoma Society Patient Education Series, Lake Oswego, OR

Advancements in CLL, Leukemia and Lymphoma Society Seminar, Portland, OR

An update on individualized kinase inhibitor therapy in acute leukemia, OHSU Center for Hematologic Malignancies Grand Rounds, Portland, OR

Targeted Therapeutics for Leukemia, OHSU Novartis Practicum: Q & A Panel on Developments in Lymphomas and Chronic Lymphoid Leukemias, Portland, OR

Chronic Lymphocytic Leukemia, Leukemia & Lymphoma Society. Oregon Blood Cancer Conference, Oregon Convention Center, Portland, OR

Targeting the BCR in lymphoid Malignancies, Knight Cancer Center Research Grand Rounds: Portland, OR

An Update on kinase inhibitors in MCL and CLL, City Wide Journal Club Portland, OR

An Update in CLL, Leukemia and Lymphoma Society Education Series, Portland, OR

2014

Waldenstrom's Macroglobulinemia: ASH update, Leukemia and Lymphoma Society Patient Support Group, Lake Oswego, OR

Obinutuzumab in CLL, Hematology/Oncology Fellows Case Conference/Journal Club: Oregon Health & Science University, Portland OR

Update in chronic lymphocytic leukemia, OHSU ASH Hematology Update, Portland, OR

What Every Fellow Should Know About CLL, OHSU Hematology/Oncology Fellows Grand Rounds: Portland, OR

Novel Therapies in Mantle Cell Lymphoma, Lymphoma Research Foundation, Portland, OR
Treatment of CLL in the Kinase Inhibitor Era, Knight Travelling CME, Good Samaritan Oncology, Corvallis, OR

2015

Waldenstrom's Macroglobulinemia: ASH update, Leukemia and Lymphoma Society Patient Support Group, Lake Oswego, OR

Kinase Inhibitors in Leukemia: A BEAT AML Status Update. OHSU Center for Hematologic Malignancies Grand Rounds, Portland, OR

What Every Fellow Should Know about CLL, fellow's conference, OHSU Knight Cancer Institute CLL ASH Update. Sentinel Hotel, Portland, OR.

Optimizing Kinase Inhibitor Therapy in Chronic Lymphocytic Leukemia. Oncology Grand Rounds, Fred Hutchinson Cancer Institute, Seattle, WA

2016

Waldenstrom's Macroglobulinemia: ASH update, Leukemia and Lymphoma Society Patient Support Group, Tualitin, OR

Kinase Inhibitors in Mantle Cell Lymphoma. Oncology Tumor Board, Tuality Hospital, Hillsboro, OR

2017

Chronic Lymphocytic Leukemia: ASH Update. Sentinel Hotel, Portland, OR.

2018

Revolutionizing the paradigm and Prognosis of B-cell Malignancies with BTK Inhibitors. Hospital Grand Rounds, Oregon Oncology Associates, Salem, OR

Chronic Lymphocytic Leukemia: ASH Update 2018. Sentinel Hotel, Portland, OR.

Updates in CLL, CLL Society, Portland, OR

Chronic Lymphocytic Leukemia, Ask the Expert, Patient Power, Portland, OR

2019

Chronic Lymphocytic Leukemia: ASH Update 2018. Sentinel Hotel, Portland, OR.

The Current State of Large Cell Lymphoma, Novartis CART Symposium, Oregon Health & Science University, Portland, OR.

B-Cell Malignancies Tumor Board: Therapeutic Decision Making in Challenging Clinical Scenarios. Lewiston, ID

2020

Opinions in Follicular Lymphoma Workshop, regional virtual roundtable discussion

2021

Navigating Evolving Paradigms in B-Cell Malignancies, CME webcast

2022

Chronic Lymphocytic Leukemia: ASH Update 2021. Embassy Suites Hotel, Portland, OR.

Living with Chronic Lymphocytic, Leukemia & Lymphoma Society, national webcast

2023

The Path Forward in Lymphoma: Oregon Society of Medical Oncology

SERVICE

Membership in Professional Societies:

2009-	American Society of Hematology (ASH)
2009-	American Society of Clinical Oncology (ASCO)
2015-	Southwest Oncology Group (SWOG)
2009-	Knight Cancer Institute (KCI)
2009-	National Cancer Institute (NCI)
2000-	Alpha Omega Honor Society (AOA)

Ad Hoc Reviewer:

2015-	Blood
2017-	Cancer Cell
2020-	Journal of Clinical Oncology
	2016-Leukemia Research
	2016-British Journal of Hematology
2014-	Leukemia
2013-	Therapeutic Advances in Hematology
2015-	Journal of Pharmacology and Experimental Therapeutics
2022-	American Journal of Hematology
2022-	Haematologica

Granting Agency Review Work

2012-2018	Resource Allocation Committee (RAC), Knight Cancer Institute, Oregon Health & Science University, Portland, OR
-----------	--

Committees:

National

2014- Present Southwest Oncology Group Lymphoma Committee/Working Group
2014-2015 NCI Lymphoma Steering Committee (LYSC) – Mantle Cell
Lymphoma Sub-Committee (Ione selected Junior Faculty Member)
2018-2019 CME faculty, Educational Concepts
2020- Chair DSMB Fred Hutchinson Cancer Center

Institutional

2005-2006 Internal Medicine Program Directors Committee, OHSU
2005-2006 Chief of Service Rounds, OHSU
2005-2006 Medicine Best Practice Group, OHSU
2005-2006 Clinical Educators Curriculum, OHSU
2010-2016 Interviewer, Internal Medicine Residency Program, OHSU
2011- Oncology Quality Oversight Committee, OHSU
2013- Cancer Committee, OHSU
2014 Joint Oncology Leadership Team, OHSU

Departmental

2007- Clinical Research Review Committee, Knight Cancer Institute, OHSU
2011- co-Chair, Clinical Research Review Committee, Knight Cancer Institute, OHSU
2010- Lymphoma-Leukemia Tumor Board
2008-2017 Hematology & Medical Oncology Fellowship Committee
2010-2019 Center for Hematologic Malignancies, Protocol Review Committee, OHSU
2011-2013 Clinical Director, Inpatient Hematologic Malignancies service, OHSU
2011-2013 Clinical and Research Director, Chronic Lymphocytic Leukemia Program
OHSU
2012-2018 Resource Allocation Committee, Knight Cancer Institute, OHSU
2012 Keizen Event, expediting clinical trials, OHSU
2013-2021 Section Chief, Hematologic Malignancies, OHSU
2013-2018 Value Stream: Project sponsor, participant, and member
management team. Center for Hematologic Malignancies, OHSU
2018-2021 Disease Site Leader for Lymphoma and CLL Research, Knight Cancer
Institute OHSU
2021- Lymphoma Program Director, Knight Cancer Institute OHSU
2021- BMT Director Search Committee

Community Service:

2004-2006 Volunteer, *Jeff Hope*, Philadelphia
2007-2008 Team Member, Making Strides Against Breast Cancer, Portland, OR,
2007-present Director, Borchard Foundation, Los Angeles, CA
2010-2013 Volunteer, Head and Neck Cancer Screening Day, OHSU
2009-2016 Volunteer Speaker, Patient Education Series, Leukemia and
Lymphoma Society

2010-2017	Volunteer Speaker, Patient Education Series, Lymphoma Research Foundation
2013-present	Volunteer, Oregon Food Bank
2010-present	Volunteer Speaker, Waldenstrom's Patient Support Group
2012-2019	Youth Basketball Coach
2021	Board Member, Cleveland High School Soccer
2024	SOLVE (Stop Oregon Litter and Vandalism) environmental cleanup

Clinical Responsibilities (since last promotion):

Currently 30% of my time is devoted to scholarship, 20% to directing the lymphoma program, 10% to teaching, and 45% devoted to service.

- 2.5- days of lymphoma clinic per week, OHSU Knight Cancer Institute, .5-1 day for documentation, chemotherapy orders, coordination of care, and clinical trial oversight
 - coordinate collection of patient samples
 - review all patients weekly with care team including APP, nursing
 - oversee care of clinical trial patients
 - assign AEs, complete CRFs/EDC entries for clinical trial patients
- 4-6 weeks inpatient attending, Lymphoma/Myeloma, Transplant/cell therapy, and Leukemia Services
 - 1-2 hours per inpatient week reviewing active cases with Leukemia team
- 1 hour per week, Multidisciplinary Lymphoma Tumor Board
- 1 day of hematology clinic per week, Celilo Cancer Center, The Dalles, OR.
- PRN (1-2 hours per month)- provide expert consultation across the Pacific Northwest

VI. TEACHING (OHSU Educators Portfolio):

Professional Development

2008-2009	Certificate	OHSU (Human Investigator Program)
2012	Pathways to Leadership	OHSU (Division of Management)

Teaching and Curriculum Development:

I am an active member of the Hematologic Malignancies Clinical Group and lead the chronic lymphocytic leukemia program (CLL) and lymphoma research programs. In this role, I oversee a team of research nurses and study coordinators and in collaboration with 3 other lymphoma MDs, outline the vision for the program and set our research priorities which often requires intramural and extramural collaboration. I also teach medical students and a broad range of trainees. I also serve as an active member of the translational research program at the Knight Cancer Institute which involves interacting with learners from multiple departments and programs.

Past and current activities include:

Classroom Student Teaching

Pathophysiology of Blood, *Chronic Lymphocytic Leukemia*, 2nd year medical student lecture, Oregon Health & Sciences University, Portland, OR, 2009-present

Pathophysiology of Blood small group facilitator, 2nd year medical students, Oregon Health & Sciences University, Portland, OR, 2009-2019

Clinical Student Teaching

Principles of Clinical Medicine, Preceptor for 1st and 2nd year medical students, Oregon Health & Sciences University, Portland, OR, 2010-2016

Lymphatic and Blood Based Cancers, OHSU Physician's Assistant Review Course, Portland, OR, 2010

Resident and Fellows Lectures/Small Group Seminars

Hematology & Medical Oncology Fellows Case Conference/Journal Club, Oregon Health & Sciences University, Portland, OR, 2009, 2014, 2015

Hematology & Medical Oncology Fellows Grand Rounds, Oregon Health & Sciences University, Portland, OR, 2010-present

Resident & Fellow Clinical Teaching

Hematology & Medical Oncology Fellows, Inpatient Hematologic Malignancies Service, Oregon Health & Sciences University, Portland, OR, 2009-present

Hematology & Medical Oncology Fellows, Outpatient Hematologic Malignancies Clinic, Oregon Health & Sciences University, Portland, OR, 2009-present

Mentorship and Advising (detailed in Educator's Portfolio, available upon request)

I have been active advising a broad range of learners and trainees including students, technicians, advance practitioners, and study coordinators. I have primarily mentored fellows in the clinic and a broad range of research projects which has led to manuscripts and investigator- initiated trials. Previously as Hematologic Malignancies Section Chief, I recruited multiple faculty members and directly oversaw the promotion of six faculty from Assistant to Associate Professor. Currently, in my role as Lymphoma Program Director, in addition to running the program and recruiting new faculty, I directly mentor 1 junior Faculty member (Tanaya Shree) and 1 nurse practitioner (Pam St. Clair) as well as a number of trainees including medical studies, fellows, hospitalists, and study coordinators. As co-chair of the Knight Cancer Institute's Clinical Research Review Committee, I mentor scientific reviewers.